title: Antibodies to hepatitis C virus in uremic patients on continuous ambulatory peritoneal dialysis.
abstract: The prevalence of antibody to hepatitis C virus (anti-HCV) among 101 uremic patients receiving continuous ambulatory peritoneal dialysis (CAPD) was evaluated using a synthetic peptide-based HCV antibodies enzyme immunoassay. Thirty (29.7%) were found anti-HCV positive. This is significantly higher than 500 unselected paid blood donors (4.2%, P less than 0.0001). Among CAPD patients, anti-HCV positivity was found more frequently in patients who had received frequent and longer duration of hemodialysis previously (40.4% vs. 20.4%, P less than 0.05). These findings suggest that hemodialysis patients have a higher risk of HCV infection. At present, CAPD may be a suitable way to reduce the incidence of HCV infection in uremic patients.
authors.affiliation: Department of Medicine, Veterans General Hospital, Taipei, Taiwan, Republic of China.
authors.forename: Y Y
authors.initials: YY
authors.lastname: Ng
authors.forename: S D
authors.initials: SD
authors.lastname: Lee
authors.forename: S C
authors.initials: SC
authors.lastname: Wu
authors.forename: W C
authors.initials: WC
authors.lastname: Yang
authors.forename: S S
authors.initials: SS
authors.lastname: Chiang
authors.forename: T P
authors.initials: TP
authors.lastname: Huang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D016174:Hepacivirus / Q000276:immunology*; D006508:Hepatitis Antibodies / Q000097:blood*; D006509:Hepatitis B / Q000453:epidemiology; D006515:Hepatitis B virus / Q000276:immunology; D006526:Hepatitis C / Q000453:epidemiology*; D018937:Hepatitis C Antibodies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D013624:Taiwan / Q000453:epidemiology; D014511:Uremia / Q000150:complications*
chemical_list: D006508:Hepatitis Antibodies; D018937:Hepatitis C Antibodies